Search
- Jul 19, 2023
Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm
Al Collinson of TheracosBio discusses his plan to sell the SGLT2 inhibitor Brenzavvy for a deeply discounted price.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A